Lai, R., Recht, L. D., Reardon, D. A., Paleologos, N., Groves, M. D., Rosenfeld, M. R., … Sampson, J. H. (2010). Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). Journal of Clinical Oncology, 28(15_suppl), 2014–2014. https://doi.org/10.1200/jco.2010.28.15_suppl.2014

Lai, R., L. D. Recht, D. A. Reardon, N. Paleologos, M. D. Groves, M. R. Rosenfeld, S. Meech, T. A. Davis, D. Pavlov, and J. H. Sampson. “Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).” Journal of Clinical Oncology 28, no. 15_suppl (May 20, 2010): 2014–2014. https://doi.org/10.1200/jco.2010.28.15_suppl.2014.

Lai R, Recht LD, Reardon DA, Paleologos N, Groves MD, Rosenfeld MR, et al. Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). Journal of Clinical Oncology. 2010 May 20;28(15_suppl):2014–2014.

Lai, R., et al. “Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM).” Journal of Clinical Oncology, vol. 28, no. 15_suppl, American Society of Clinical Oncology (ASCO), May 2010, pp. 2014–2014. Crossref, doi:10.1200/jco.2010.28.15_suppl.2014.

Lai R, Recht LD, Reardon DA, Paleologos N, Groves MD, Rosenfeld MR, Meech S, Davis TA, Pavlov D, Sampson JH. Interim data for ACT III: Phase II trial of PF-04948568 (CDX-110) in combination with temozolomide (TMZ) in patients (pts) with glioblastoma (GBM). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2010 May 20;28(15_suppl):2014–2014.